BioCryst Pharmaceuticals (United States)

Recent papers from BioCryst Pharmaceuticals (United States)

1. BCX9250 is a potent small-molecule inhibitor of ALK2 for fibrodysplasia ossificans progressiva (FOP)JBMR Plus · 2026
2. Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study ResultsClinical and Translational Allergy · 2026
3. Optimizing conversations on treatment management in hereditary angioedema: healthcare professional and patient perspectives on long-term prophylaxis and shared decision-makingAllergy Asthma and Clinical Immunology · 2026
4. Berotralstat and Health‐Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX ‐2 and APeX ‐J TrialsClinical & Experimental Allergy · 2026
5. Optimizing Titanium Osseointegration through Thermally Modified Co-Doped Monetite CoatingsACS Biomaterials Science & Engineering · 2026
6. Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-worldAllergy Asthma and Clinical Immunology · 2026
7. Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedemaAnnals of Allergy Asthma & Immunology · 2025
8. Absolute Configuration of Key Intermediates and the Gram Scale Synthesis of Berotralstat and ent-BerotralstatThe Journal of Organic Chemistry · 2025
9. Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedemaAnnals of Allergy Asthma & Immunology · 2025
10. Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United StatesJournal of Managed Care & Specialty Pharmacy · 2025
11. Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United StatesAllergy and Asthma Proceedings · 2025
12. First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Complement Factor D Inhibitor BCX9930 in Healthy ParticipantsThe Journal of Clinical Pharmacology · 2025
13. Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)The Journal of Allergy and Clinical Immunology In Practice · 2025
14. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe Journal of Allergy and Clinical Immunology In Practice · 2025
15. Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy2024
16. Regioselective alkylation of a versatile indazole: Electrophile scope and mechanistic insights from density functional theory calculationsBeilstein Journal of Organic Chemistry · 2024
17. Developing Therapies for C3 GlomerulopathyClinical Journal of the American Society of Nephrology · 2024
18. Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trialSHILAP Revista de lepidopterología · 2024
19. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized TrialThe Journal of Allergy and Clinical Immunology In Practice · 2023
20. Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trialWorld Allergy Organization Journal · 2023